Literature DB >> 19029408

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

Robin K Kelley1, Alan P Venook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19029408     DOI： 10.1200/JCO.2008.19.7996

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

3.  A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma.

Authors:  Xiaozhou Yu; Hua Zhao; Liang Liu; Shui Cao; Baozhu Ren; Naining Zhang; Xiumei An; Jinpu Yu; Hui Li; Xiubao Ren
Journal:  J Clin Immunol       Date:  2013-12-15       Impact factor: 8.317

4.  Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).

Authors:  Yu Yang; Jiang Zhu; Hongfeng Gou; Dan Cao; Ming Jiang; Mei Hou
Journal:  Med Oncol       Date:  2010-04-17       Impact factor: 3.064

5.  A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

Authors:  Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O'Neil; Ruey-Min Lee; Mark Zalupski; Janet Dancey; Helen Chen; Michael Grever; Charis Eng; Miguel Villalona-Calero
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.

Authors:  Lei Huang; Guang-Ming Li; Ji-Ye Zhu; Zhao Li; Tao Li; Xi-Sheng Leng
Journal:  Onco Targets Ther       Date:  2012-12-20       Impact factor: 4.147

7.  Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma.

Authors:  P K H Chow; D Machin; Y Chen; X Zhang; K-M Win; H-H Hoang; B-D Nguyen; M-Y Jin; R Lobo; M Findlay; C-H Lim; S-B Tan; M Gandhi; K-C Soo
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

8.  Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.

Authors:  Omar Abdel-Rahman; Manal Abdel-Wahab; Mohammed Shaker; Sherif Abdel-Wahab; Mohammed Elbassiony; Mahmoud Ellithy
Journal:  Med Oncol       Date:  2013-07-04       Impact factor: 3.738

9.  Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma.

Authors:  Hong Ni; Mao Yang; Zhi Guo; Ti Zhang
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

10.  Anticancer effects of bufalin on human hepatocellular carcinoma HepG2 cells: roles of apoptosis and autophagy.

Authors:  Qing Miao; Lin-Lin Bi; Xin Li; Shan Miao; Jin Zhang; Song Zhang; Qian Yang; Yan-Hua Xie; Jian Zhang; Si-Wang Wang
Journal:  Int J Mol Sci       Date:  2013-01-11       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.